WO2013014843A1 - 標的物質の検出方法、センサチップ、及び検出装置 - Google Patents
標的物質の検出方法、センサチップ、及び検出装置 Download PDFInfo
- Publication number
- WO2013014843A1 WO2013014843A1 PCT/JP2012/003538 JP2012003538W WO2013014843A1 WO 2013014843 A1 WO2013014843 A1 WO 2013014843A1 JP 2012003538 W JP2012003538 W JP 2012003538W WO 2013014843 A1 WO2013014843 A1 WO 2013014843A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- aptamer
- acid fragment
- double
- target substance
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6825—Nucleic acid detection involving sensors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6823—Release of bound markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
Definitions
- the present invention relates to a target substance detection method, a sensor chip, and a detection apparatus.
- Aptamers refer to nucleic acids (DNA, RNA, PNA) having the ability to bind to specific substances.
- Substances to be bound by aptamers are diverse, such as biomolecules such as proteins, hormones and peptides, artificial molecules such as agricultural chemicals, and small molecules such as potassium ions. Therefore, the target substance contained in the specimen can be quantified by detecting the binding between the aptamer and the target substance. Further, a sensor that specifically responds to the target substance can be constructed by taking out the binding between the aptamer and the target substance as an electric signal.
- Patent Documents 1 and 2 and Non-Patent Documents 1 to 4 When detecting substances using aptamers, the aptamers are supported on solids because of the advantages such as easy handling of aptamers during solution exchange, etc., and easy handling of many aptamers at the same time.
- Patent Documents 1 and 2 and Non-Patent Documents 1 to 4 For example, Patent Documents 1 and 2 and Non-Patent Documents 1 to 4).
- Non-Patent Documents 1 and 2 describe sensors in which aptamers 101 and 121 labeled with methylene blue as electrode reactants 103 and 113 are fixed on electrodes 104 and 114 (FIG. 1A). To (d)). These sensors change the three-dimensional structure generated in the aptamers 101 and 121 by the binding of the target substance (the target substance 107 such as thrombin or cocaine 127), and the change in the distance between the electrodes 104 and 114 and the electrode reactants 103 and 113. That is, it is detected as a change in the reaction current of the electrode reactants 103 and 113.
- the target substance the target substance 107 such as thrombin or cocaine 127
- the manner and amount of change in the three-dimensional structure of the aptamer due to the binding to the target substance vary greatly depending on the aptamer. That is, as shown in FIG. 1C, the electrode reactant 113 may be separated from the electrode 114 after the aptamer 121 has changed in structure. On the other hand, as shown in FIG. 1 (d), the electrode reactant 113 may approach the electrode 114 after the aptamer 121 changes its structure. Therefore, when the distance between the labeling substance and the electrode is advantageously greatly changed, and a sensor is formed using the methods of Non-Patent Documents 1 and 2, aptamers that can obtain a sufficient signal change are limited. That is, the techniques of Non-Patent Documents 1 and 2 have room for improvement in terms of detection accuracy.
- Patent Document 1 describes a technique that improves the detection mechanism of the presence of a target substance. That is, in Patent Document 1, an aptamer sensor using an aptamer 101 and its complementary strand 102 is described as shown in FIG. According to this document, it is described that the presence of a target substance can be detected by the following mechanism. That is, in the aptamer sensor, the aptamer 101 and the complementary strand 102 form a double-stranded nucleic acid region (double-stranded formation site 105) by forming a complementary base pair in the absence of the target substance (FIG. 2 (a )).
- the target substance 107 when the target substance 107 is present, the complementary base pair formation is dissociated and eliminated as the aptamer 101 and the target substance 107 are bound (FIG. 2B).
- the target substance is detected by detecting changes in physical and chemical properties caused thereby. For example, it is described that the presence of the target substance can be detected by detecting that the complementary strand 102 having the electrode reactive substance 103 is separated from the electrode 104 (surface plasmon resonance sensor substrate).
- the double strand of the aptamer and the complementary strand is maintained before the target substance binds to the aptamer.
- the double strand is dissociated according to the dissociation equilibrium reaction.
- the complementary strand separates from the aptamer and diffuses into the sample solution.
- the probability that the complementary strand diffused in the solution binds to the aptamer again is very low. For this reason, the number of duplexes of the aptamer and the complementary strand gradually decreases, and detection of the target substance may be hindered.
- the design of the double-stranded formation site of the conventional aptamer is very difficult due to such conflicting properties of the double-strand maintenance ability and the double-strand cleavage ability.
- the present invention has been made in view of the above circumstances, and an object of the present invention is to provide a highly reliable method for detecting a target substance by using an aptamer and a nucleic acid fragment that have improved mutually contradictory characteristics. It is to provide.
- An aptamer that specifically binds to a target substance in a sample and A first nucleic acid fragment having a base sequence complementary to the aptamer; A fixing member to which a part of the aptamer and a part of the first nucleic acid fragment are fixed; With The aptamer has a double-strand formation site that forms a double strand with the first nucleic acid fragment, and a step of preparing a complex; Separating the first nucleic acid fragment from the duplex-forming site of the aptamer by binding the target substance to the aptamer; Detecting the double-strand cleavage, wherein the first nucleic acid fragment is separated from the aptamer; There is provided a method for detecting a target substance having
- An aptamer that specifically binds to a target substance in a sample and A first nucleic acid fragment having a base sequence complementary to the aptamer; A fixing member to which a part of the aptamer and a part of the first nucleic acid fragment are fixed, and The aptamer is composed of a complex having a double-stranded forming site that forms a double strand with the first nucleic acid fragment.
- a sensor chip for use in detecting a target substance is provided.
- the sensor chip A binding part for binding a target substance to the aptamer; A detection unit for detecting the cleavage of the double strand; An apparatus for detecting a target substance is provided.
- a method for detecting a target substance with excellent reliability is provided.
- the method for detecting a target substance 7 includes the following steps. First, the composite 11 is prepared.
- the complex 11 includes an aptamer 1, a first nucleic acid fragment 2, and a fixing member 4.
- the aptamer 1 specifically binds to the target substance 7 in the specimen sample (test object).
- the aptamer 1 has a double strand forming site 5 that forms a double strand with the first nucleic acid fragment 2.
- the first nucleic acid fragment 2 has a base sequence complementary to the aptamer 1. A part of the aptamer 1 and a part of the first nucleic acid fragment 2 are fixed to the fixing member 4.
- the target substance 7 is bound to the aptamer 1.
- the first nucleic acid fragment 2 is separated from the aptamer 1 and double-strand cleavage is detected.
- the cleavage of the double strand means that, for example, the first nucleic acid fragment 2 is fixed from the double strand formation site 5 of the aptamer 1 in a state where the first nucleic acid fragment 2 is fixed to the fixing member 4. It means to separate. Further, being fixed to the fixing member 4 means being bonded by chemical bonding and / or chemical adsorption, excluding the hydrogen bond constituting the double strand formation. Various known means can be used as a method for detecting double-strand cleavage, which will be described later in detail.
- the aptamer 1 has a double strand forming site 5 that forms a double strand with the first nucleic acid fragment 2.
- a part of the first nucleic acid fragment 2 is fixed to the fixing member 4 like the part of the aptamer 1. Even if the first nucleic acid fragment 2 is separated from the aptamer 1 when the target substance 7 is not bound, a part of the first nucleic acid fragment 2 is fixed to the fixing member 4. For this reason, the first nucleic acid fragment 2 is difficult to diffuse into the solution as in the prior art. Such a first nucleic acid fragment 2 can form a double strand again with the aptamer 1.
- the design of the double strand formation site 5 of the aptamer 1 can be adapted to the double strand cleavage ability.
- the double-stranded maintenance ability is realized by fixing a part of the first nucleic acid fragment 2 to the fixing member 4 separately from the double-stranded forming site 5 of the aptamer 1. That is, the ability to maintain double strands and the ability to cleave double strands are not imparted only to the double-strand formation site, and the ability to maintain double strands is imparted to a part of the immobilized first nucleic acid fragment 2, The chain cleavage ability can be imparted to the double-strand formation site 5. This makes it possible to distribute the two functions to different parts.
- the complex 11 of the present embodiment it is possible to achieve both the double-strand maintenance ability and the double-strand cleavage ability, which are mutually contradictory characteristics in the conventional technique.
- excellent detection of the target substance can be realized.
- the aptamer 1 that specifically binds to the target substance is identical to the nucleic acid fragment (first nucleic acid fragment 2) having a base sequence complementary to the aptamer.
- Preparation step of the complex fixed to the member of the sample by chemical bonding and chemical adsorption, contact step of bringing the complex into contact with the specimen, binding step of binding the target substance in the specimen to the aptamer, aptamer and nucleic acid on the member A cleavage step of cleaving a double-stranded nucleic acid site by the fragment, and a detection step of detecting the double-stranded nucleic acid site of the aptamer and the nucleic acid fragment.
- the composite 11 is prepared.
- This complex 11 has an aptamer 1, a first nucleic acid fragment 2, and a fixing member 4.
- the end of the aptamer 1 and the end of the first nucleic acid fragment 2 are fixed to the fixing member 4 by chemical bonding and chemical adsorption.
- the end of the aptamer 1 and the end of the first nucleic acid fragment 2 are directly fixed to the fixing member 4.
- at least a part of the base sequence capable of forming a bond with the target substance forms the first nucleic acid fragment 2 and the double-stranded formation site 5 (FIG. 6 (a)).
- the double-stranded forming site 5 (double-stranded nucleic acid site) means a site where an aptamer and a nucleic acid having a complementary sequence thereof form a double-stranded nucleic acid. .
- the target substance 7 binds to the aptamer 1 (FIG. 6B).
- the aptamer 1 has a part of the base sequence capable of forming a bond with the target substance forming a double-stranded forming site 5, but the other site is in a single-stranded state. That is, the structure of the single-stranded part of the aptamer 1 can be freely deformed.
- the aptamer 1 has a double-strand formation site 5 with the first nucleic acid fragment 2 and a binding site capable of binding to the target substance 7. Therefore, the aptamer 1 can take a three-dimensional structure as an aptamer and can bind to the target substance 7 in the test object.
- the double strand at the double strand formation site 5 formed between the aptamer 1 and the first nucleic acid fragment 2 is cleaved. That is, when the aptamer 1 and the target substance 7 are bound in the first step, the double-strand formation site 5 is eliminated due to branch migration. This branch migration occurs when the binding between the target substance 7 and the aptamer 1 is stronger than the binding between the nucleic acids forming the double-stranded nucleic acid site of the aptamer 1. When the double-stranded nucleic acid site of the aptamer 1 disappears in this manner, the aptamer 1 is dissociated from the first nucleic acid fragment 2 (FIG. 6 (c)).
- the first nucleic acid fragment 2 remains in a state of being fixed to the fixing member 4.
- the base sequence of the aptamer 1 to which the target substance 7 binds is common to a part or all of the base sequence of the double-stranded forming site of the aptamer 1. For this reason, when the target substance 7 binds to the aptamer 1, the structure in the double-stranded nucleic acid site of the aptamer 1 is deformed, and the aptamer 1 and the first nucleic acid fragment 2 are cleaved.
- the detection of cleavage at the double strand formation site of the aptamer 1 is not limited as long as the physical and chemical changes caused by the double strand cleavage at the double strand nucleic acid site can be detected. It means detecting a signal change such as an electrical signal or a color signal.
- Patent Document 1 described above describes that only one of aptamer and nucleic acid fragment is directly fixed to a member. That is, the document describes that when an aptamer is directly fixed to a member, the nucleic acid fragment is fixed to the aptamer by forming a double strand with the aptamer without being fixed to the member.
- the binding force between the aptamer and the nucleic acid fragment may be insufficient.
- the double-stranded nucleic acid site is eliminated according to the double-stranded dissociation equilibrium reaction.
- the non-fixed nucleic acid diffuses in the solution immediately after the double-stranded nucleic acid site is eliminated and leaves the member surface. For this reason, once a double-stranded nucleic acid site is eliminated, there is very little possibility that a double-stranded nucleic acid site will be formed again. Therefore, even when the target substance is absent, the double-stranded nucleic acid site decreases with time, which hinders detection of the target substance.
- the aptamer 1 and the first nucleic acid fragment 2 are fixed to the same fixing member 4 by chemical bonding and chemical adsorption, so that these nucleic acids are attached to the surface of the member. It will be in a locally concentrated state. Then, the frequency with which the aptamer 1 and the first nucleic acid fragment 2 come into contact increases, and the apparent binding constant increases. Therefore, the aptamer 1 in the first embodiment can shorten the length of the double-stranded formation site 5 required for stably forming a double-stranded nucleic acid state, thereby Adverse effects on binding ability due to strand nucleic acid formation are reduced.
- Non-Patent Document 3 a technique in which only an aptamer is directly fixed to a member is described in Non-Patent Document 3 in addition to Patent Document 1 described above, for example.
- the thrombin aptamer 111 is fixed to the electrode 104.
- the complementary strand 102 forms a double strand with the thrombin aptamer 111 at two double strand forming sites 105 and 106.
- This complementary strand 102 is labeled with methylene blue (electrode reactant 113) (FIG. 3 (a)).
- thrombin 117 is added, the double-stranded formation site 106 is eliminated (FIG. 3B). And the mobility of methylene blue is improved.
- Thrombin 117 is detected by improving the reaction current of methylene blue.
- the double-stranded formation site 105 is not completely eliminated. For this reason, there is little improvement in the mobility of methylene blue before and after the addition of thrombin, and the amount of current change is small (about 1-2% with respect to the base current).
- the first nucleic acid fragment 2 can move freely with respect to the aptamer 1 after the double strand of the double strand forming site 5 is cleaved. That is, the first nucleic acid fragment 2 does not form a double strand with the aptamer 1 after the target substance 7 is bound to the aptamer 1.
- the complementary strand 102 described in Non-Patent Document 3 forms a double strand at the thrombin aptamer 111 and the double strand formation site 105 after the thrombin 117 is bound to the thrombin aptamer 111.
- the first nucleic acid fragment 2 of the present embodiment can move freely with respect to the aptamer 1 by the amount that does not have a portion bound over a predetermined region of the double-stranded formation site 5. For this reason, the mobility of the labeling substance 3 of the present embodiment is higher than that of the non-patent document 3, and the current change amount of the present embodiment is also increased. Therefore, according to this Embodiment, the measuring method of the target substance excellent in detection accuracy is realizable.
- the chemical bond and chemisorption do not include hydrogen bond bonding between nucleic acid molecules such as complementary base pair formation.
- the three-dimensional structure of the aptamer and the nucleic acid fragment is changed.
- the double-stranded formation site 5 cannot be sufficiently formed, or the binding between the aptamer 1 and the target substance 7 is inhibited. This is because the detection of the target substance 7 is hindered.
- Patent Document 2 describes an aptamer sensor array in which one end of an aptamer incorporating a molecular beacon mechanism is fixed on a substrate (electrode 104) (FIG. 4).
- the modifying substance 109 is bonded to the end of the aptamer.
- the modifying substance 109 for functioning the beacon may inhibit the binding with the aptamer due to steric hindrance or the like.
- the sequence near the center of the aptamer becomes a double-strand-unformed site 110.
- the double-strand non-forming site 110 has a limitation that it cannot be used as a double-stranded nucleic acid region for operating the beacon mechanism.
- Non-Patent Document 4 describes an aptamer in which a base sequence unrelated to the binding ability of aptamer (margin sequence 136) is added to the extension of aptamer sequence 131 (FIG. 5). It is described that a part of the double-stranded forming region 135 is a marginal sequence 136 to balance the hybridization formation and the aptamer binding ability. However, in this case, the site where the marginal sequence 136 can be added is limited to the end of the aptamer. For this reason, the marginal arrangement 136 has a limitation that it cannot be applied to an aptamer whose structural change in the central part is larger than that in the end part.
- aptamers that cause a large structural change in the sequence of the central part of the aptamer due to the binding of the target substance cannot form a double-stranded nucleic acid site in the central part of the sequence.
- the double-stranded forming site 5 of the aptamer 1 of the present embodiment can be a base sequence that does not include a marginal sequence.
- the duplex forming site 5 of the aptamer 1 has only a base sequence complementary to the base sequence of the first nucleic acid fragment 2.
- part 5 can be set besides the edge part of an aptamer. That is, the double-strand formation site 5 can be formed at a site where cleavage is likely to occur in the presence of the target substance 7 such that the steric structure changes greatly when bound to the target substance 7. Therefore, a large signal change can be obtained.
- the test object does not include a substance that binds to the aptamer 1
- the aptamer does not bind to the substance in the test object, and the double strand in the double-strand formation site 5 is It will not be resolved. Therefore, by detecting the cleavage at the double-stranded nucleic acid site formed between the aptamer 1 and the first nucleic acid fragment 2, it can be detected whether or not the target substance 7 is contained in the test object.
- the aptamer 1 is a nucleic acid that can specifically bind to the target substance 7 and is complementary to the first nucleic acid fragment 2 that can form a double-stranded site 5. What is necessary is just to have a base sequence.
- the aptamer 1 may be, for example, DNA or RNA, or may be an artificial nucleic acid such as PNA.
- aptamer 1 is not particularly limited, aptamer 1 preferably has an aptamer structure that specifically binds to an epitope of target substance 7, and may partially have a structural portion that does not bind to target substance 7.
- the aptamer 1 can be obtained using, for example, a known aptamer screening method such as the SELEX method. Further, if necessary, a nucleic acid sequence obtained by SELEX or the like plus a desired base sequence may be synthesized. By adding the base sequence, the distance between the aptamer and the substrate is increased to reduce steric hindrance, or the length of the double-stranded nucleic acid region of the aptamer 1 and the complementary strand (first nucleic acid fragment 2) is adjusted. Thus, the strength of the binding force between the two can be adjusted.
- the duplex formation site 5 between the aptamer 1 and the first nucleic acid fragment 2 may be in any part of the aptamer 1, for example, at the end of the aptamer or in the center. Good. Further, the entire sequence of the single-stranded nucleic acid of the aptamer 1 may form the double-stranded forming site 5. However, the double-strand formation site 5 here is formed so as to include a part of the base sequence that binds to the target substance 7 in order to facilitate branch migration when the target substance 7 and the aptamer 1 are bound. The length is preferably 2 to 20 bases, more preferably 4 to 15 bases, and further preferably 6 to 12 bases. In addition, the aptamer 1 may be modified with the labeling substance 3 as necessary in order to facilitate the detection of the double-stranded formation site 5.
- the first nucleic acid fragment 2 has a complementary base sequence that can form a double-stranded nucleic acid site with the aptamer 1, for example, DNA, RNA, PNA, etc. Can be used.
- the first nucleic acid fragment 2 may have a non-complementary base sequence in addition to a base sequence complementary to the aptamer 1 as a part thereof. By adding a non-complementary base sequence, it can be used as a spacer between the nucleic acid fragment and the substrate, or between the labeling substance 3 and the nucleic acid fragment, and steric hindrance can be reduced.
- the double-stranded nucleic acid site with the aptamer 1 may be in any part of the first nucleic acid fragment 2, for example, in the end part or in the center part.
- the first nucleic acid fragment 2 may be modified with a labeling substance 3 as necessary in order to facilitate detection of a double-stranded nucleic acid site.
- a spacer is formed between the base sequence forming the double-strand formation site 5 between the aptamer 1 and the first nucleic acid fragment 2 and the substrate. That is, it is preferable that a first spacer is formed on the aptamer 1 and a second spacer is formed on the first nucleic acid fragment 2.
- the first spacer and the second spacer are simply referred to as a spacer.
- the length of the first spacer may be the same as or different from the length of the second spacer. This spacer is preferably 3 mm or more.
- the spacer is preferably 200 mm or less. Thereby, it can suppress that the concentration effect by the aptamer and the nucleic acid fragment being fixed close to the member surface is impaired. More preferably, the spacer is 10 to 50 mm. Such a spacer is not particularly limited as long as it does not form a bond between the aptamer and the nucleic acid fragment, and is not a complementary nucleic acid, sugar chain, polypeptide, hydrocarbon chain, oligoethylene glycol, etc.
- the first spacer is different from the base sequence of the second spacer, that is, does not have a complementary base sequence.
- the number of bases in the spacer is preferably 8 or less, more preferably 7 or less.
- the number of bases of the spacer is appropriately determined according to the detection method.
- the number of bases in the spacer is more preferably 7 or less.
- the number of bases may be, for example, 8 or more, or 12 or more.
- the end of the aptamer 1 and the end of the first nucleic acid fragment 2 have a functional group for fixing to the member by chemical bonding and chemical adsorption.
- a functional group is not limited as long as it can form a bond that does not dissociate with the member depending on the solvent and pH conditions used, and is not limited to carboxyl group, amino group, thiol group, disulfide group, succinimidyl.
- a general group such as a group, a maleimide group, or biotin can be used.
- These functional groups can be prepared by a general nucleic acid synthesis method, or those formed by modifying those nucleic acids with a commercially available linker or the like can be used.
- the functional group may be modified at any site as long as it does not interfere with the specific binding between the aptamer and the target substance, for example, it may be at the end of the aptamer 1 and the first nucleic acid fragment 2, It may be in the center.
- the design margin of the aptamer 1 can be improved.
- the formation efficiency and stability of the double-stranded nucleic acid site can be changed, and the target substance of the first embodiment
- the response characteristic in the detection method can be changed.
- the target substance when the abundance ratio of the nucleic acid fragment is increased with respect to the aptamer, many aptamers on the surface of the member are in a state where double-stranded nucleic acid sites are formed. In this case, since there are few aptamers in a single-stranded nucleic acid state, the target substance efficiently binds to an aptamer that has formed a double-stranded nucleic acid site, and cleaves the double-stranded nucleic acid site. Therefore, high detection sensitivity can be obtained even when the concentration of the target substance is low.
- the aptamer abundance ratio is increased with respect to the nucleic acid fragment, most of the nucleic acid fragments on the surface of the member are in a state where double-stranded nucleic acid sites are formed.
- the S / N when the cleavage of the double-stranded forming site 5 is detected by the labeling substance 3 modified to the first nucleic acid fragment 2 can be improved. it can.
- the abundance ratio of the aptamer and the nucleic acid fragment on the surface of the member is not particularly limited and can be appropriately set according to the aptamer sequence, the ionic strength, temperature, etc. of the measurement solution. It is preferred that the aptamer / nucleic acid fragment molar fraction be between 0.05 and 20 so as not to reduce too much.
- the material of the fixing member 4 according to the first embodiment is not particularly limited as long as the aptamer 1 and the first nucleic acid fragment 2 can be fixed, or can be processed so as to be fixed.
- Examples of a method for immobilizing a nucleic acid on a member include a method of forming a peptide bond using a functional group of a nucleic acid and a functional group on the surface of the member, and the presence of gold, platinum, silver, palladium, etc. on the member surface.
- There are a method of chemically adsorbing a thiol group of a nucleic acid on the surface a method of forming a biotin-avidin bond by immobilizing avidin on the surface of a member, and the like.
- a method of growing nucleic acids sequentially using functional groups on the surface of the member may be used.
- a desired functional group may be formed by treating the member with thiol or a silane coupling agent.
- a substrate particles such as beads, or a microarray chip may be used.
- the shape of a member is not specifically limited, For example, any of plate shape or spherical shape may be sufficient.
- the complex 11 is constructed.
- An annealing treatment may be performed in order to increase the formation rate of double-stranded nucleic acid sites.
- the treatment conditions may be general conditions used for forming a double-stranded nucleic acid, and are appropriately set based on the length and type of complementary base pairs of the sequence to be used, the salt concentration, and the like. Further, annealing can be appropriately performed after each nucleic acid solution, a mixed solution thereof, or after fixing them to a member.
- the fixing member 4 may perform a blocking treatment after fixing the aptamer 1 and the first nucleic acid fragment 2.
- a blocking treatment By blocking the nonspecific substance adsorbing on the surface of the member by blocking treatment, false positives can be reduced and S / N can be improved, or the aptamer 1 and the first nucleic acid fragment 2 can be moved substantially vertically from the member. By making it stand up, the binding rate between the target substance and the aptamer can be increased and the sensitivity can be increased.
- Blocking treatments are generally performed using hydrophilic polymers such as polyethylene glycol and acrylamide, proteins such as bovine serum albumin, sugar chains such as dextrin, lipids such as phosphatidylcholine, and hydrophilic thiols such as mercaptohexanol.
- a blocking agent can be used.
- the target substance detection method according to the first embodiment is usually performed in a solution containing a test object.
- the solution may be a general reaction solution.
- conditions such as temperature at the time of performing each process, pH, a metal ion, are set appropriately.
- the method for detecting a target substance according to the first embodiment uses a double-stranded portion of a nucleic acid, temperature conditions, pH, and the like that can maintain double-stranded binding of the nucleic acid are desirable.
- the method for detecting cleavage at the double-strand formation site 5 formed between the aptamer 1 and the first nucleic acid fragment 2 is not particularly limited.
- a technique for detecting a physical / chemical change of the nucleic acid itself and the labeling substance 3 generated by cleavage of the nucleic acid site of this strand can be used.
- the physical / chemical change is not particularly limited, but color change, fluorescence change, dielectric constant change, electron transfer effect change, mass change, viscosity change, heat change, etc. can be used.
- fluorescent substance is labeled.
- FRET fluorescence resonance energy transfer
- a method using a double-stranded nucleic acid indicator such as SYBR (registered trademark) Green I that intercalates and fluoresces a double-stranded nucleic acid site can be used.
- a change in charge density on the surface of the member due to cleavage of double-stranded nucleic acid, a change in distance between the labeling substance 3 and the surface of the member, a change in contact frequency, etc. can be detected by surface plasmon resonance (SPR), surface acoustic wave (SAW) You may detect by well-known methods, such as an effect transistor (FET) and an electrochemical measurement.
- SPR surface plasmon resonance
- SAW surface acoustic wave
- the labeling substance 3 according to the first embodiment is not limited as long as it can amplify a physical / chemical change caused by the cleavage of the double-strand formation site 5.
- a fluorescent substance or a quencher is used.
- the cleavage of the double-stranded nucleic acid site is detected by quartz crystal microbalance (QCM)
- QCM quartz crystal microbalance
- the weight of the nucleic acid itself such as FET or SPR, or a change in dielectric constant
- the modifying substance for the nucleic acid may be omitted.
- the labeling substance 3 is labeled at the tip of the first nucleic acid fragment 2.
- the end of the aptamer 1 and the end of the first nucleic acid fragment 2 are fixed to a fixing member 4 that is an electrode to form a complex 11.
- the base sequence of the aptamer 1 and the base sequence of the first nucleic acid fragment 2 have consecutive complementary sequences so that the distance between the labeling substance 3 and the fixing member 4 is not close.
- the fixing member 4 is connected to an electrochemical measurement device together with a counter electrode and a reference electrode (not shown).
- the test substance contains the target substance 7
- the target substance 7 binds to the double-stranded nucleic acid site of the aptamer 1 (FIG. 6B), and the aptamer 1 moves away from the first nucleic acid fragment 2 (FIG. 6). 6 (c)).
- the contact frequency of the labeling substance 3 and the fixing member 4 is recovered.
- the reaction current of the labeling substance 3 is recovered. Therefore, the reaction current of the labeling substance 3 becomes larger when the target 7 is brought into contact with the aptamer 1.
- the aptamer 1 continues to bind to the first nucleic acid fragment 2, so that the reaction current of the labeling substance 3 does not change.
- the presence or absence of the target substance 7 can be examined by comparing the reaction current before and after contacting the test object.
- the measurement before contacting the inspection object can be omitted as necessary.
- the surface of the member may be cleaned as necessary during or during each step.
- the sensor chip including the complex 11 can be used for detecting the target substance 7. That is, this sensor chip includes an aptamer 1 to which a target substance 7 in a specimen sample specifically binds, a first nucleic acid fragment 2 having a base sequence complementary to the aptamer 1, a part of the aptamer 1, and a first A fixing member 4 to which a part of the nucleic acid fragment 2 is fixed, and the aptamer 1 has a double-stranded forming site 5 that forms a double strand with the first nucleic acid fragment 2. Consists of a complex 11. In the sensor chip, the double-stranded forming site 5 formed by the aptamer 1 and the first nucleic acid fragment 2 may not include a marginal sequence.
- the double-stranded formation site 5 may be formed other than the end of the aptamer 1.
- the aptamer 1 and the first nucleic acid fragment 2 are provided with a connecting portion bonded by chemical bonding and chemical adsorption, and at least one of the connecting portions is formed by chemical bonding and chemical adsorption. It may be fixed to the member.
- the composite 11 can appropriately adopt the one of each embodiment.
- the double-strand formation site 5 is cleaved by the binding between the target substance 7 and the aptamer 1. Thereby, the effect of this Embodiment is acquired.
- the target substance 7 detection apparatus includes the sensor chip, a binding unit that binds the target substance 7 to the aptamer 1, and a detection unit that detects double-strand cleavage. Prepare.
- the binding unit brings the test object including the target substance 7 into contact with the complex 11.
- the coupling unit may contact the sensor chip and the target substance 7.
- the detection unit for detecting the cleavage of the double-stranded nucleic acid site is not limited as long as it can detect a physical or chemical change caused by the cleavage of the double-stranded nucleic acid site. For example, an optical signal, an electrical signal, a color Detection of signal changes, such as dynamic signals.
- this target substance detection apparatus even if the target substance has a low concentration, a large signal change occurs and high measurement sensitivity can be obtained by the target substance detection method described above. Further, by using a sensor chip in which the aptamer is appropriately changed according to the substance to be detected, it can be used for detection of various target substances.
- the complex 11 includes a connecting part 8 in which a part of the aptamer 1 and a part of the first nucleic acid fragment 2 are connected to each other, and the connecting part 8 is fixed to the fixing member 4.
- the aptamer 1 and the first nucleic acid fragment 2 are linked by chemical bonding and chemical adsorption.
- a part of the aptamer 1 and a part of the first nucleic acid fragment 2 may be bound to a linker molecule.
- FIG. 7 is a diagram illustrating the complex 11 according to the second embodiment.
- the aptamer 1 and the first nucleic acid fragment 2 are provided with a connecting portion 8 that is bonded by chemical bonding and chemical adsorption, and the connecting portion 8 has at least one chemical bond. And it is fixed to the fixing member 4 by chemical adsorption.
- the aptamer 1 and the first nucleic acid fragment 2 are connected to each other, thereby accurately controlling the fixed state of the aptamer 1 and the first nucleic acid fragment 2 on the surface of the fixing member 4. become able to. As a result, the background of the measured value is reduced, the variation of the sensor chip is reduced, and the measurement reliability and detection sensitivity are improved.
- the complex 11 is prepared.
- the aptamer 1 and the first nucleic acid fragment 2 are linked by chemical bonding and chemical adsorption, excluding the hydrogen bond that constitutes the double strand, to form a linking part 8.
- the linking part 8 means a site where the aptamer 1 and the first nucleic acid fragment 2 are linked.
- the connecting portion 8 is fixed to the fixing member 4 by chemical bonding and chemical adsorption excluding the hydrogen bonds constituting the double strand.
- the immobilized aptamer 1 and the first nucleic acid fragment 2 form a double strand forming site 5 by a complementary base sequence to form a complex 11.
- the complex 11 thus prepared can be used for detection of a target substance using the presence or absence of cleavage of a double-stranded nucleic acid site as an index, as in the method of the first embodiment.
- the aptamer 1 and the first nucleic acid fragment 2 are connected to each other and then fixed to the member, so that the aptamer 1 and the first nucleic acid fragment 2 are fixed in a state of being close to each other. Then, the double strand formation site 5 comes to be formed efficiently. Therefore, in the target substance detection method of the second embodiment, the background is reduced and the measurement sensitivity is improved.
- the sensor chip according to the second embodiment has reduced manufacturing variations and improved yield.
- the detection method of the target substance of 2nd Embodiment can adjust the formation efficiency and stability of a double stranded nucleic acid site
- the aptamer 1 and the first nucleic acid fragment 2 can be the same as those in the first embodiment, but the functional groups of the aptamer 1 and the first nucleic acid fragment 2 are What can form the connection part 8 is used suitably.
- the formation of the connection is not particularly limited, and a general chemical reaction can be used.
- the connection part 8 has a functional group for forming a chemical bond and chemical adsorption with the fixing member 4.
- a linking method for example, after the aptamer 1 and the first nucleic acid fragment 2 are bonded to two functional groups of a linker molecule having three different functional groups, the remaining functional groups are fixed to the member. Is mentioned.
- a nucleic acid in which a modified base containing a functional group for binding to a member, a linker molecule, and the like are inserted between an aptamer sequence and a nucleic acid fragment may be synthesized by a general nucleic acid synthesis method.
- a linker is not particularly limited, and various commercially available reagents can be used.
- Dithiol Phosphoramidite manufactured by Glen research
- the fixing member 4 can be the same as that in the first embodiment, and preferably has a functional group for fixing to the connecting portion 8 as necessary.
- the linked aptamer 1 and the first nucleic acid fragment 2 are fixed to the member at one point via the connecting portion 8, but the fixing between the connecting portion and the member is There may be multiple places.
- the structure is not limited to the three-branch type as shown in FIG. 7A, and linker molecules having various chemical structures can be used. As shown in b), it may have a ladder structure, or a multi-branched linker molecule may be used so that the aptamer / nucleic acid fragment linking ratio is other than 1: 1.
- the length of the linker molecule is not particularly limited, but is preferably 3 mm or more in order to prevent the formation efficiency of double-stranded nucleic acid sites from being reduced due to steric hindrance between the aptamer and the nucleic acid fragment. In order not to impair the concentration effect due to being fixed in the vicinity of the member surface, it is preferably 200 mm or less.
- FIG. 8 is a diagram illustrating a procedure of a target substance detection method according to the third embodiment.
- the aptamer 1 and the first nucleic acid fragment 2 are fixed to the fixing member 4, and the aptamer 1 and the first nucleic acid fragment 2 form a double-stranded forming site 5.
- the cleavage of the double-stranded nucleic acid site by the target substance 7 is detected using the second nucleic acid fragment 10.
- the step of detecting the cleavage of the double strand is performed by adding the first nucleic acid fragment 2 to the first nucleic acid fragment 2 separated from the double strand formation site 5.
- the composite 11 is prepared in the same manner as in the first and second embodiments.
- the aptamer 1 and the first nucleic acid fragment 2 of the complex form a double-stranded nucleic acid site with a complementary base sequence (FIG. 8 (a)).
- the second nucleic acid fragment 10 having a base sequence capable of forming a bond with a base sequence complementary to the first nucleic acid fragment 2 is added to the measurement solution in advance.
- the labeling substance 3 is modified in advance on the second nucleic acid fragment 10.
- the second nucleic acid fragment 10 is bound to the first nucleic acid fragment 2 (FIG. 8C).
- the first nucleic acid fragment 2 forms a double strand formation site 5 with the aptamer 1 fixed to the same fixing member 4. That is, since the first nucleic acid fragment 2 and the aptamer 1 are locally concentrated on the member surface, the apparent binding constant of the double-stranded forming site 5 is high. For this reason, the second nucleic acid fragment 10 present in the solution cannot overcome the competitive reaction with the aptamer 1 and dissociate the double-stranded forming site 5, and cannot bind to the first nucleic acid fragment 2. Absent.
- the second nucleic acid fragment 10 can form a complementary base pair with the first nucleic acid fragment 2.
- the second nucleic acid fragment 10 bound to the first nucleic acid fragment 2 is detected.
- the detection of the second nucleic acid fragment 10 bound to the first nucleic acid fragment 2 is caused by the labeling substance 3 of the second nucleic acid fragment 10 bound to the fixing member 4 via the first nucleic acid fragment 2. It is not limited as long as a physical and chemical change can be detected, and for example, it means detecting a signal change such as an optical signal, an electrical signal, and a color signal.
- the bond between the aptamer 1 and the first nucleic acid fragment 2 is not cleaved. Does not bind to nucleic acid fragment 2. Therefore, by detecting the second nucleic acid fragment 10 bound to the first nucleic acid fragment 2, it is possible to detect whether or not the target substance 7 is contained in the test object.
- a high S / N is obtained because the background level is low when the labeling substance 3 does not exist on the fixing member 4 and does not bind. Therefore, according to the third embodiment, the target substance can be detected with high sensitivity.
- the second nucleic acid fragment 10 is added prior to the contact between the test object and the complex 11, but the second nucleic acid fragment is composed of the aptamer 1 and the first nucleic acid fragment 2. It only needs to be present when cleavage occurs, and the addition timing is not particularly limited.
- the second nucleic acid fragment 10 is particularly preferably present in the measurement solution when the target substance 7 and the complex 11 come into contact with each other.
- the first nucleic acid fragment 2 in a single-stranded state generated by cleavage of the double-stranded forming site 5 of the complex 11 quickly binds to the second nucleic acid fragment 10.
- the aptamer 1 separated from the first nucleic acid fragment 2 releases the target substance 7 according to the equilibrium reaction to be in a single-stranded state, recombination with the first nucleic acid fragment 2 is inhibited. Therefore, even when the target substance 7 is at a low concentration, dissociation between the aptamer 1 and the first nucleic acid fragment 2 proceeds, and a large signal can be obtained.
- the second nucleic acid fragment 10 has a complementary base sequence capable of forming a double-stranded nucleic acid site with the first nucleic acid fragment 2, and for example, DNA, RNA, PNA, etc. are used. be able to. Further, the second nucleic acid fragment 10 may have a non-complementary base sequence in addition to a base sequence complementary to the first nucleic acid fragment 2 as a part thereof.
- the double-stranded nucleic acid site with the first nucleic acid fragment 2 may be in any part of the second nucleic acid fragment 10, for example, at the end or at the center.
- the second nucleic acid fragment 10 includes a fluorescent substance, a quencher, an electrochemical reaction substance, a polar substance,
- the labeling substance 3 such as an enzyme or a catalyst may be modified.
- the number of complementary bases between the second nucleic acid fragment 10 and the first nucleic acid fragment 2 depends on the strength of the bond between the aptamer 1 and the first nucleic acid fragment 2. Depending on the optimum value. That is, when the target substance is absent, the number of bases is not so large that the bond between the aptamer 1 and the first nucleic acid fragment 2 is weak enough not to peel off, and in the presence of the target substance, The number of bases is so large that two nucleic acid fragments 10 and the first nucleic acid fragment 2 can be stably combined in a solution.
- the specific number of bases varies depending on the base sequence and salt strength of the aptamer 1 and the first nucleic acid fragment 2, but the number of complementary bases is 8 bases or more as a guideline for a value that can be stably bound in solution,
- the number is preferably equal to or more than the number of complementary bases between the aptamer 1 and the first nucleic acid fragment 2, and more preferably more than two bases.
- the surplus number of complementary bases relative to the number of complementary bases between the aptamer 1 and the first nucleic acid fragment 2 is It is preferably 10 bases or less.
- the fixing member 4 has a solvophilic region (supplementary part 14) in a region different from the fixing region (detection unit 13) to which the aptamer 1 and the first nucleic acid fragment 2 are fixed.
- the supplement part 14 has high affinity with a solvent, it can supplement the second nucleic acid fragment 10 contained in the solvent by penetrating the surface thereof.
- the second nucleic acid fragment 10 captured by the supplement unit 14 moves on the surface thereof, and can easily bind to the first nucleic acid fragment 2 fixed to the detection unit 13.
- FIG. 9 is a diagram showing the procedure of the target substance detection method in the fourth embodiment.
- the aptamer 1 and the first nucleic acid fragment 2 are fixed to a part of the fixing member 4.
- the entire fixing member 4 is a solvophilic member.
- the fixing member 4 is not limited to this aspect, and only a part of the supplementary portion 14 may be a solvophilic member.
- a part or the whole of the surface of an arbitrary member may be subjected to a solvophilic treatment.
- the second nucleic acid fragment in which the labeling substance 3 is modified in advance as in the third embodiment. 10 is used.
- the portion of the solvophilic fixing member 4 where nucleic acids such as aptamers and nucleic acid fragments are fixed is hereinafter referred to as a detection unit 13.
- the target substance detection method of the fourth embodiment will be described with reference to FIG.
- the aptamer 1 and the first nucleic acid fragment 2 are fixed to the detection unit 13 of the fixing member 4 by chemical bonding and chemical adsorption.
- the aptamer 1 fixed to the detection unit 13 and the first nucleic acid fragment 2 form a double-strand formation site 5 with a complementary base sequence (FIG. 9A).
- a measurement solution containing the target substance 7 and the second nucleic acid fragment 10 is brought into contact with a part (the supplement part 14) other than the detection part 13 of the fixing member 4.
- the measurement solution comes into contact with a member having solvophilic properties, the target substance 7 and the second nucleic acid fragment 10 penetrate into the member together with the solution (FIG. 9B).
- the aptamer 1 of the detection unit 13 and the target substance 7 are combined.
- the target substance 7 in the liquid comes into contact with the aptamer 1.
- the aptamer 1 and the target substance 7 are bound, and the double-stranded nucleic acid site between the aptamer 1 and the first nucleic acid fragment 2 is cleaved (FIG. 9 (c)).
- the second nucleic acid fragment 10 binds to the first nucleic acid fragment 2 of the detection unit 13 (FIG. 9 (d)). Since the aptamer 1 fixed to the member in the previous step is bound to the target substance 7, the binding ability between the aptamer 1 and the first nucleic acid fragment 2 is also lost. Therefore, the second nucleic acid fragment 10 can form a complementary base pair with the first nucleic acid fragment 2.
- the target substance is detected by measuring a physical and chemical change generated in the detection unit 13 by the labeling substance 3 of the second nucleic acid fragment 10 bound to the fixing member 4 through the first nucleic acid fragment 2.
- the first nucleic acid fragment 2 and the second nucleic acid fragment 10 are bonded by forming a complementary base pair by the above-described steps.
- the second nucleic acid fragment 10 is the first nucleic acid fragment 2 because the double strand formation site 5 by the aptamer 1 and the first nucleic acid fragment 2 is not eliminated. Do not combine with. Therefore, by measuring the physical and chemical changes that occur in the detection unit 13 by the labeling substance 3 of the second nucleic acid fragment 10 bound to the fixing member 4 via the first nucleic acid fragment 2, It can be determined whether or not the target substance is contained.
- the specimen that has contacted the solvophilic member spontaneously penetrates the member and the examination proceeds, the specimen can be easily handled and the target substance can be easily examined. be able to.
- Non-Patent Document 6 As a method for detecting a target substance that fixes an aptamer to a solvophilic member, for example, a lateral flow method is reported in Non-Patent Document 6.
- the reported conventional method performs detection by forming a so-called sandwich structure in which an aptamer fixed to a member with respect to a target substance is bound to a labeled aptamer. Therefore, it is necessary to prepare at least two types of aptamers that recognize different epitopes of the target substance, which requires a lot of labor for acquiring aptamers.
- the detection method of the fourth embodiment if one kind of aptamer is prepared, it is possible to detect the target substance, and the labor for acquiring the aptamer can be saved.
- the solvophilic member used in the fourth embodiment is not particularly limited as long as it comes into contact with the contacted measurement solution, but is a material whose contact angle with respect to the sample or the solvent for diluting the sample is less than 90 degrees. Is preferably used.
- the member is porous, the penetration of the solution occurs quickly due to capillary action, or the amount of aptamer immobilized increases and the signal at the time of target substance binding increases, thereby reducing the time required for detection. An effect such as an increase in detection sensitivity is obtained, which is preferable.
- the porous filter etc. by glass fiber, nitrocellulose, a cellulose, a synthetic fiber, a nonwoven fabric etc. are mentioned, for example.
- solvophilic member not shown in FIG. 9 may be laminated or connected to the solvophilic fixing member 4 to which the aptamer and the nucleic acid fragment are fixed.
- the member containing the second nucleic acid fragment and the member having the detection unit can be prepared separately, and there are advantages such as easy manufacture.
- the method of chemically bonding and chemisorbing the aptamer and the nucleic acid fragment to the solvophilic member can be performed by using a method such as using a functional group as in the first to third embodiments. Good.
- a method for fixing the aptamer 1 and the first nucleic acid fragment 2 to the detection unit 13 is not particularly limited. For example, a part of the member is masked, or the solution of the aptamer 1 and the first nucleic acid fragment 2 is reacted with the member. At this time, the reaction solution may be spotted, for example, so that the fixing reaction occurs only in a part of the solvophilic fixing member 4.
- measuring the physical and chemical changes occurring in the detection unit 13 is not limited as long as the physical and chemical changes caused by the presence of the labeling substance 3 in the detection unit 13 can be measured.
- measuring signal changes such as optical signals, electrical signals, color signals, etc.
- the labeling substance 3 is not particularly limited, and for example, a coloring substance, an electrochemical reaction substance, and a catalyst substance can be used.
- a chromogenic substance When a chromogenic substance is used, the color of the detection portion changes when the second nucleic acid fragment 10 binds to the nucleic acid fragment, and the inspection result can be easily discriminated visually or with a simple image sensor.
- color forming substances include metal fine particles that generate surface plasmons such as pigments, colored beads, and gold nanoparticles.
- an electrochemical reaction substance when used, a conductive substance is installed in the vicinity of the detection unit, and by using it as the working electrode of the electrochemical reaction, the binding between the second nucleic acid fragment and the nucleic acid fragment can be detected as a current change, It becomes possible to convert the inspection result into an electric signal by a simple device.
- electrochemically reactive substances include metals, metal complexes, quinones and derivatives thereof, derivatives of methylene blue, pyrroles, heterocyclic compounds such as pyridine and viologen, and the like.
- a catalyst substance when a catalyst substance is used, color development or a change in electrochemical reaction characteristics can be caused in the detection unit depending on the combination of the catalyst used and the substrate or electron transfer mediator.
- the second nucleic acid fragment 10 binds to the first nucleic acid fragment 2
- a reaction that causes the above-described color development or change in electrochemical reaction characteristics occurs continuously in the detection unit 13 and the signal is amplified.
- the target substance can be detected with higher sensitivity.
- catalytic substances examples include oxidases such as glucose oxidase and bilirubin oxidase, dehydrogenases such as glucose dehydrogenase, coenzyme oxidases such as diaphorase, peroxide reductases such as horseradish peroxidase and catalase, Pt and Aptamers capable of binding to metal catalysts such as titanium oxide, catalytic nucleic acids such as ribozymes and deoxyribozymes, and catalytically active substances such as hemin aptamers can be used.
- the electron transfer mediator and the substrate can be appropriately selected according to the type of enzyme and catalyst used.
- These labeling substances can be easily modified into nucleic acid fragments by general reactions such as amine coupling, gold-thiol reaction, and nucleic acid extension synthesis.
- the measurement liquid containing the target substance 7 and the second nucleic acid fragment 10 is in contact with the solvophilic fixing member 4 in FIG. 9B, but the fourth embodiment In the detection of the target substance, it is sufficient that the second nucleic acid fragment 10 is present in the measurement solution when the target substance 7 comes into contact with the aptamer 1.
- Two nucleic acid fragments 10 may be impregnated, or the sample and the liquid containing the second nucleic acid fragment 10 may be mixed in advance and then contacted with a solvophilic member.
- the step of binding the second nucleic acid fragment 10 includes the step of binding the second nucleic acid immobilized on the substrate (member 21) to the first nucleic acid fragment 2 separated from the double strand forming site 5.
- This substrate (member 21) has a solvophilic region (supplementary part 14) in a region different from the fixed region (detection part 13) to which the second nucleic acid fragment 10 is fixed. Note that this embodiment is an application of the first to fourth embodiments, and description of similar points is omitted.
- FIG. 11 is a diagram illustrating a procedure of a target substance detection method according to the fifth embodiment.
- the target substance detection apparatus (FIG. 11A) according to the fifth embodiment includes a sample introduction unit 15, a complex holding unit 16, and a member 21.
- the sample introduction part 15 is a solvophilic member.
- the complex holding part 16 is a solvophilic member into which the complex 11 has been impregnated in advance.
- the member 21 is a solvophilic member in which the second nucleic acid fragment 10 is fixed to the detection unit 13.
- complex 11 of 5th Embodiment has the following structure.
- the aptamer 1 and the first nucleic acid fragment 2 are fixed to the same fixing member 4 by chemical bonding and chemical adsorption.
- the fixing member 4 is in the form of fine particles such as microspheres and microfibers.
- the labeling substance 3 is modified on the fixing member 4.
- the aptamer 1 and the first nucleic acid fragment 2 form a double strand forming site 5 with a complementary base sequence.
- the target substance detection method in the fifth embodiment will be described with reference to FIG.
- an inspection object including the target substance 7 is injected into the sample introduction unit 15.
- the solution of the inspection object penetrates into the sample introduction unit 15 and then penetrates into the complex holding unit 16.
- the sample introduction unit 15 is in contact with the complex holding unit 16.
- the target substance 7 contained in the liquid penetrates into the complex holding part 16 (FIG. 11B).
- the solution is further immersed and penetrates into the member 21.
- the complex 11 of the complex holder 16 is eluted in the measurement solution.
- the complex 11 penetrates into the member 21 together with the solution and the target substance 7.
- the target substance 7 binds to the aptamer 1 of the complex 11.
- the duplex forming site 5 of the aptamer 1 and the first nucleic acid fragment 2 is cleaved.
- the penetration of the solution further proceeds, and the complex 11 in which the double-stranded nucleic acid site is cleaved reaches the detection unit 13. Then, the first nucleic acid fragment 2 and the second nucleic acid fragment 10 that do not form a double-stranded nucleic acid site form a double-stranded nucleic acid site, and the complex 11 binds to the detection unit 13.
- the target substance is detected by detecting the labeling substance 3 present in the detection unit 13.
- the labeling substance 3 is present in the detection unit 13 by binding the complex 11 including the labeling substance 3 to the detection unit 13 through the above-described process.
- the complex 11 does not bind to the detection unit 13 because the double-stranded formation site 5 formed by the aptamer 1 and the first nucleic acid fragment 2 is not eliminated.
- the labeling substance 3 does not exist in the part 13. Therefore, it is possible to determine whether or not the target substance is contained in the inspection object by measuring the physical and chemical changes generated in the inspection unit 13 by the labeling substance 3.
- the target substance can be detected even if the second nucleic acid fragment 10 is immobilized on the detection part of the solvophilic member. That is, in the present embodiment, any one of the aptamer 1 and the first nucleic acid fragment 2 or the second nucleic acid fragment 10 is fixed to the detection part of the solvophilic member (fixing member 4 or member 21). .
- the double-strand cleavage between the aptamer 1 and the first nucleic acid fragment 2 can be detected.
- the fixing member 4 is not particularly limited as long as the fixing member 4 is a fine particle having dispersibility with respect to the solvent of the solution to be injected into the sample introduction unit. Can be used.
- the labeling substance can be omitted when the microparticles cause a change in physical and chemical properties in the detection part due to the characteristics of the microparticles themselves, such as metal microparticles and colored beads that are colored by surface plasmon absorption.
- the same substances as those described in the fourth embodiment can be used.
- the labeling substance 3 is modified with the fixing member 4 which is a fine particle.
- the binding between the aptamer and the target substance or the binding between the first nucleic acid fragment and the second nucleic acid fragment is inhibited, It may be modified to a fragment or aptamer.
- sample introduction unit, the complex holding unit, and the solvophilic member according to the fifth embodiment can be the same as the solvophilic member described in the fourth embodiment.
- the sample introduction part and the complex holding part are arranged in a substantially horizontal shape, but the invention is not limited thereto, and each part may be laminated.
- the target substance detection step of the present embodiment includes a cleavage energy input step that weakens the binding strength of the double strand between the aptamer and the first nucleic acid fragment, and the double strand binding between the aptamer and the first nucleic acid fragment. It includes a double-stranded stabilization process that strengthens the force.
- the sixth embodiment will be specifically described with reference to FIGS. 12 and 13. Note that the sixth embodiment is an application of the first to fifth embodiments, and description of similar points is omitted.
- FIG. 12 is a diagram showing a target substance detection step when energy equal to or higher than the binding energy between the aptamer and the first nucleic acid fragment is input in the cleavage energy input step.
- the complex 11 in which the aptamer 1 and the first nucleic acid fragment 2 are fixed to the fixing member 4 is formed by the same complex preparation process as in the first to fifth embodiments (FIG. 12A).
- the double-stranded bond between the aptamer 1 and the first nucleic acid fragment 2 in the complex 11 is weakened by a cleavage energy input step. Since the input cleavage energy is equal to or higher than the binding energy between the aptamer 1 and the first nucleic acid fragment 2, the aptamer 1 and the first nucleic acid fragment 2 cannot maintain the double-stranded state and are cleaved. At this time, since the aptamer 1 and the first nucleic acid fragment 2 are both fixed to the fixing member 4, they are in a single-stranded state and exist on the surface of the member (FIG. 12 (b)).
- the target substance 7 is bound to the aptamer 1.
- the target substance 7 can easily bind to the single-stranded aptamer 1 (FIG. 12 (c)).
- the aptamer maintains a single-stranded state (FIG. 12 (e)).
- the binding between the aptamer 1 and the first nucleic acid fragment 2 is strengthened by a double-stranded stabilization step.
- the sample includes the target substance 7, since the target substance 7 is already bound to the aptamer 1 in the previous step, formation of double-stranded bonds by the aptamer 1 and the first nucleic acid fragment 2 is inhibited. (FIG. 12D).
- the sample does not contain a target substance, the single-stranded aptamer 1 and the first nucleic acid fragment 2 are recombined to form a double strand (FIG. 12 (f)).
- the target substance is detected by a double strand cleavage detection step. That is, the double strand is cleaved when the target substance is present (FIG. 12 (d)), and is not cleaved when the target substance is absent (FIG. 12 (f)).
- the presence or absence of the target substance can be distinguished by using the presence or absence of double-strand cleavage as an index.
- the detection sensitivity and reliability of the target substance are improved by dynamically changing the double-stranded binding force between the aptamer and the first nucleic acid fragment during the target substance detection step. That is, at the stage where the aptamer and the target substance bind, by weakening the double-strand binding force, the double-strand maintenance ability is suppressed and the double-strand cleavage ability is enhanced. As a result, the aptamer quickly dissociates the double strand from the first nucleic acid fragment and binds to the target substance when the target substance is present. Therefore, double-strand cleavage is likely to occur even with a low concentration of target substance, and the detection sensitivity of the target substance is improved.
- the double-strand cleavage detection step by strengthening the double-strand binding force, the double-strand maintenance ability is enhanced and the double-strand cleavage ability is suppressed.
- the aptamer and the nucleic acid fragment dissociated by the input of the cleavage energy rapidly re-form a double strand when the target substance is absent. Therefore, double-strand dissociation in the absence of the target substance is suppressed, and detection reliability is improved.
- an excellent target substance detection method in which detection sensitivity and reliability are compatible is provided.
- the complex 11 (FIG. 13 (a)) formed by the complex preparation step is in a double-stranded state in which the binding energy is weakened by adding cleavage energy (FIG. 13 (b)).
- the double strand in which the binding energy is weakened is in a state in which the double strand maintenance ability is weakened and the double strand cleavage ability is enhanced. Therefore, when the target substance 7 is present in the specimen, the aptamer 1 and the target substance 7 are easily bound, and the double strand is cleaved (FIG. 13 (c)).
- the aptamer 1 bound to the target substance 7 maintains the cleaved state even after the double strand stabilization step (FIG. 13 (d)).
- the aptamer maintains the destabilized double-stranded state (FIG. 13 (e)), and the stable double-stranded state is obtained by the subsequent double-stranded stabilization step. It returns to the state (FIG. 13 (f)).
- the input of cleavage energy means any means for weakening the binding force based on the complementary base sequence generated between the aptamer and the first nucleic acid fragment, and the method is not particularly limited.
- a technique for example, an operation such as increasing the temperature, increasing the pH, decreasing the salt strength, or increasing the concentration of the organic solvent is performed on the measurement liquid, or the measurement liquid is exchanged with such a liquid. And so on.
- the cleavage energy is input before or simultaneously with the step of binding the target substance to the aptamer.
- the double-stranded stabilization step means any means for strengthening the binding force based on the complementary base sequence generated between the aptamer and the first nucleic acid fragment, and its method is particularly limited. Not. As such a technique, for example, operations such as lowering the temperature, neutralizing the pH, increasing the salt strength, or lowering the organic solvent concentration are performed on the measurement liquid, or the measurement liquid is changed to such a liquid. Such as exchanging.
- the double-stranded stabilization step is performed after the step of binding the target substance to the aptamer, and is performed before or simultaneously with the step of detecting the double-strand cleavage.
- both the aptamer and the first nucleic acid fragment are fixed to a fixing member. It shows a particularly remarkable effect.
- both the aptamer and the first nucleic acid fragment are immobilized on the immobilization member, the ability to maintain double strands is suppressed by the introduction of cleavage energy, and even if the double strand cleavage unrelated to the target substance is likely to occur, both Stays on the member surface.
- a target substance is absent, a double strand can be rapidly reformed by a double strand stabilization step.
- the labeling substance 3 is labeled at the tip of the first nucleic acid fragment 2.
- the end of the aptamer 1 and the end of the first nucleic acid fragment 2 are fixed to a fixing member 4 that is an electrode to form a complex 11.
- the fixing member 4 is connected to an electrochemical measurement device together with a counter electrode and a reference electrode (not shown).
- the temperature of the measurement solution is raised to the double-stranded melt temperature of the aptamer 1 and the first nucleic acid fragment 2 by a heating unit (not shown).
- a heating unit not shown
- half of the aptamer 1 and the first nucleic acid fragment 2 dissociate the double strands into a single strand state (FIG. 12 (b)). That is, the act of heating the measurement liquid to the melt temperature means that a cleavage energy equal to the double-stranded bond energy is input.
- the inspection object is brought into contact with the composite 11.
- the target substance 7 binds to the single-stranded aptamer 1 (FIG. 12 (c)).
- the aptamer 1 maintains a single-stranded state (FIG. 12 (e)).
- the temperature of the measurement liquid is lowered to room temperature by a cooling unit (not shown).
- a cooling unit not shown.
- the double-stranded bond between the aptamer 1 and the first nucleic acid fragment 2 is stabilized again.
- the binding of the aptamer 1 and the target substance 7 inhibits the formation of double strands by the aptamer 1 and the second nucleic acid fragment.
- the chain remains in the cleaved state (FIG. 12 (d)).
- the aptamer 1 and the second nucleic acid fragment form a double strand again (FIG. 12 (f)).
- the case where the measurement liquid is heated to a temperature lower than the melt temperature corresponds to the case where cleavage energy equal to or lower than the binding energy between the aptamer 1 and the first nucleic acid fragment 2 is input.
- the effect of weakening the binding force between the aptamer 1 and the first nucleic acid fragment 2 can be obtained if the temperature of the measurement solution is higher than that before the heating.
- the effect of promoting the cleavage of such double-stranded sites can be obtained.
- the temperature after heating is preferably lower than the melt temperature by less than 10 ° C, more preferably less than 5 ° C. This is because, within this temperature range, the aptamer and the nucleic acid fragment undergo thermal cleavage to cause partial cleavage of the double-stranded part, which is suitable for obtaining the effect of promoting the cleavage of the double-stranded part in the presence of the target substance. .
- ATP adenosine triphosphate
- FIG. 15 shows the ATP aptamer (sequence 2) and the nucleic acid fragment (sequence 3) complementary to the ATP aptamer used in this example.
- the ATP aptamer is a sequence that does not bind to ATP as a spacer at the 5 ′ end with respect to the base sequence of the ATP aptamer that forms a bond with ATP (sequence 1 in FIG. 15).
- DNA having a thiol group modified at the 5 ′ end was used as a functional group for immobilization.
- the nucleic acid fragment has 7 bases complementary to sequence 2 and 5 bases which are not complementary as spacers between the substrate and the nucleic acid fragment, and further, methylene blue which is an electrode reactant as a labeling substance at the 5 ′ end.
- DNA modified with (MB) and a thiol group which is a functional group for fixing to the substrate at the 3 ′ end was used. Sequences 2 and 3 were synthesized using the DNA synthesis service of Tsukuba Oligo Service Co., Ltd.
- ATP aptamer and the nucleic acid fragment were dissolved in a fixed buffer (20 mM Tris-HCl, 500 mM NaCl, pH 7.4) to 100 nM, sealed in a plastic tube, and annealed at 95 ° C. for 3 minutes. The tube was then bathed in ice for 5 minutes and allowed to stand at room temperature for 30 minutes.
- a gold electrode manufactured by BAS whose surface was cleaned by alumina polishing was immersed for 1 hour, and the ATP aptamer and the nucleic acid fragment were immobilized on the gold electrode surface.
- the electrode surface was rinsed with ultrapure water, and immersed in a fixed buffer in which 1 mM mercaptohexanol was dissolved for blocking for 1 hour.
- this electrode After rinsing this electrode with ultrapure water, it was immersed in a glass cell filled with a measurement solution (20 mM tris, 300 mM NaCl, 5 mM MgCl 2 (pH 7.4)) and connected to the working electrode of a potentiostat (CompactStat manufactured by Ivium Technology). did. Further, the reaction current of methylene blue was measured by alternating current voltammetry (ACV) by connecting a platinum wire to a counter electrode terminal and a silver / silver chloride electrode (manufactured by BAS) to a reference electrode terminal. The measurement was repeated at 20 second intervals, and ATP was added so that the final concentration was 1 mM 400 seconds after the start of the measurement.
- ACCV alternating current voltammetry
- FIG. 14 shows the time variation of the ACV peak current in the above measurement.
- the current value was normalized based on the peak current immediately before the addition of ATP.
- the peak current started to increase immediately after the addition of ATP, and finally showed a value about 1.7 times that before the addition. Since the current value before addition of ATP was almost constant, it can be said that this increase in current is specific to ATP.
- ATP aptamer and nucleic acid fragment fixed on the same electrode are fixed in proximity to each other, so that the apparent binding constant increases, and 7 bases that do not form a double-stranded nucleic acid site in solution.
- a double-stranded nucleic acid site is formed by the complementary base sequence. Then, the mobility of methylene blue labeled on the nucleic acid fragment is lowered, and the contact frequency between the methylene blue and the electrode is lowered, whereby the reaction current of methylene blue in ACV measurement is suppressed.
- ATP which is a target substance of the aptamer
- the double-stranded nucleic acid site is cleaved by binding of ATP and the ATP aptamer.
- the mobility of methylene blue is restored, and the reaction current of methylene blue in ACV increases.
- the ATP aptamer that specifically binds to ATP and its complementary nucleic acid fragment (sequence 3 in FIG. 15) are immobilized based on the target substance detection method of the present invention. It can be said that ATP, which is the target substance, could be detected by using the electrode, which is the formed member.
- Example 2 Simulation of Embodiment 3 Detection of cleavage of a double-stranded nucleic acid site between an aptamer and a nucleic acid fragment by addition of the second nucleic acid fragment according to the third embodiment of the present invention is performed by simulation. investigated.
- sequences 4 to 6 (FIG. 15) were used as DNA sequence conditions.
- the buffer conditions were (300 mM Na +, 5 mM Mg2 +, pH 7.4), and the solution temperature was 37 ° C.
- sequence 4 is DNA in which an ATP aptamer and its complementary nucleic acid fragment are linked
- sequence 5 is the second nucleic acid fragment in the third embodiment.
- Sequence 6 is a base sequence obtained by removing the base sequence of the aptamer from Sequence 4, and corresponds to Sequence 4 that has lost the ability to bind to a nucleic acid fragment due to binding of the sequence portion of the ATP aptamer to ATP.
- sequence 4 27 bases that specifically bind to ATP and 7 bases corresponding to a nucleic acid fragment complementary to a part of the 27 bases are linked by 13 bases that are both linkers.
- Sequence 5 is composed of 7 bases that are complementary to the entire region of the nucleic acid fragment in sequence 4 and bases that are complementary to 5 bases that are a linker sequence continuous from the nucleic acid fragment.
- FIG. 16 shows the results of determining the ratio of the abundance of the DNA forming the double-stranded nucleic acid site to the abundance of the total DNA for the sequences 4 and 5 and the sequences 6 and 5.
- sequence 4 and sequence 5 coexist, both form a double-stranded nucleic acid site with 2% complementary base sequences.
- about 97% of the sequence 4 formed a double-stranded nucleic acid site with the sequence portion of the ATP aptamer that the sequence 4 and the nucleic acid fragment portion have. That is, in this state, the adjacent ATP aptamer and the nucleic acid fragment form a double-stranded nucleic acid region, so that the second nucleic acid fragment, sequence 5, is almost double-stranded with the nucleic acid fragment portion of sequence 4. Does not form nucleic acid sites.
- sequences 6 and 5 coexist, 85% of them form a double-stranded nucleic acid site. That is, when ATP is added and ATP binds to the base sequence that binds to ATP in sequence 4, the double-stranded nucleic acid site with the nucleic acid fragment portion is eliminated, sequence 5 as the second nucleic acid fragment is sequence 6 A double-stranded nucleic acid site can be easily formed with the nucleic acid fragment portion.
- ATP was detected by the method for detecting a target substance of the present invention using nucleic acid fragments having different numbers of bases complementary to the ATP aptamer. That is, in this example, ATP detection ability was compared when the lengths of the double-stranded nucleic acid sites were different.
- FIG. 15 shows the ATP aptamer (sequence 2) and nucleic acid fragments (sequences 7 and 8) complementary to the ATP aptamer used in this example.
- Sequence 2 is identical to the ATP aptamer of the first example.
- the nucleic acid fragment of sequence 7 has 9 bases complementary to sequence 2 and 5 non-complementary bases that are spacers.
- the nucleic acid fragment of sequence 8 has 5 bases complementary to sequence 2 and 5 bases that are not complementary as spacers. That is, when sequence 2 and sequence 7 are immobilized on the same member, the double-stranded nucleic acid site has 5 bases, and when the sequences 2 and 8 are combined, the double-stranded nucleic acid site has 9 bases. When the sequence 2 and the sequence 3 in Example 1 are combined, the double-stranded nucleic acid site has 7 bases.
- Array 2 and Array 7, and Array 2 and Array 8 were immobilized on a gold electrode in the same manner as in Example 1, and ATP was added to a final concentration of 1 mM while performing ACV measurement.
- FIG. 17 shows the correlation between the number of bases in the double-stranded nucleic acid site and the peak current of ACV before ATP addition and 400 seconds after addition in the above measurement and the measurement in Example 1. Note that the ACV peak current is normalized by the peak current before the addition of ATP in Example 1.
- the current value increased after the addition of ATP, and it can be applied to the detection of ATP by the method of the present invention.
- the amount of change in peak current before and after addition, and the rate of change showed the largest value when 7 bases were used.
- the current value tended to decrease as the number of bases in the double-stranded nucleic acid site increased.
- the double-stranded nucleic acid site is too short, the stability of the double-stranded nucleic acid site is too low and the formation efficiency of the double-stranded nucleic acid site is significantly reduced. Therefore, the rate of change and the amount of change in the double-stranded nucleic acid site before and after the addition of the target substance are reduced, which hinders detection of the target substance with high sensitivity.
- the double-stranded nucleic acid site is too long, the stability of the double-stranded nucleic acid site is too high, and the double-stranded nucleic acid site is difficult to cleave even after the addition of the target substance. Therefore, the rate of change and the amount of change in the double-stranded nucleic acid site before and after the addition of the target substance are reduced, which hinders detection of the target substance with high sensitivity.
- the target substance can be detected effectively by appropriately setting the length of the double-stranded nucleic acid site based on parameters such as the configuration of the base sequence forming the double-stranded nucleic acid site. Can do.
- ATP is detected by the method for detecting a target substance of the present invention using an ATP aptamer and a nucleic acid fragment having different spacer lengths between a double-stranded nucleic acid site and a substrate. did. That is, in this example, the ATP detection capability when the spacer lengths were different was compared.
- FIG. 15 shows ATP aptamers (sequences 9 to 11) and nucleic acid fragments complementary to ATP aptamers (sequences 12 to 14) used in this example.
- the arrays 9 to 11 and the arrays 12 to 14 are the same as in the first embodiment except that the lengths of the spacer arrays are different.
- the spacer length is 7 bases.
- the spacer length in the case of the combination of the sequence 10 and the sequence 13 is 3 bases, and in the case of the combination of the sequence 11 and the sequence 14, it is 1 base.
- the number of bases forming the double-stranded nucleic acid site is 7 bases, and the base sequence is also the same.
- Array 9 and Array 12, Array 10 and Array 13, and Array 11 and Array 14 were immobilized on a gold electrode in the same manner as in Example 1, and the ATP was adjusted to a final concentration of 1 mM while performing ACV measurement. Was added.
- FIG. 18 shows the correlation between the number of bases of the spacer and the ACV peak current before addition of ATP and after 400 seconds of addition in the above measurement and the measurement of Example 1. Note that the ACV peak current is normalized by the peak current before the addition of ATP in Example 1.
- the base forming the double-stranded nucleic acid site is located at a short distance from the substrate. Then, the steric hindrance from the substrate is strongly received, and the formation of the double-stranded nucleic acid site is inhibited. Therefore, the aptamer and nucleic acid fragment immobilized on the substrate are in a state where the double-stranded nucleic acid site is cleaved even before the addition of ATP. In addition, due to steric hindrance from the substrate, formation of a secondary structure for the aptamer to form a bond with the target substance is also inhibited.
- the spacer is too long, the concentration effect due to the aptamer and the nucleic acid fragment being fixed in the vicinity of the member surface is reduced. Then, the formation efficiency of the double-stranded nucleic acid site is lowered, and the aptamer and the nucleic acid fragment immobilized on the substrate are in a state in which the double-stranded nucleic acid site is cleaved even before the addition of ATP.
- the cleavage of a double-stranded nucleic acid site is detected by an electrochemical reaction of a labeling substance modified with a nucleic acid fragment, a high current is observed independent of ATP addition.
- the spacer part can be freely changed, if the spacer part is long, the labeling substance can come into contact with the electrode surface even in a state where a double-stranded nucleic acid part is formed. Therefore, when the cleavage of the double-stranded nucleic acid site is detected by the electrochemical reaction of the labeling substance modified to the nucleic acid fragment as in this example, the influence when the spacer is too long is particularly remarkable.
- the target substance can be effectively detected by appropriately setting the spacer length to an optimal value.
- Example 5 Concentration dependence
- the same aptamer and nucleic acid fragment as in the first example were used, and the concentration dependence of ATP concentration and current value was examined.
- the ATP aptamer of sequence 2 and the nucleic acid fragment of sequence 3 were immobilized on the electrode surface. While performing ACV measurement with the electrode, ATP was gradually added to the measurement solution.
- the correlation between ATP concentration and peak current is shown in FIG.
- the peak current was normalized with the peak current before adding ATP.
- the peak current increased depending on the ATP concentration.
- the target substance present in the measurement solution can be detected and quantified by detecting the cleavage of the double-stranded nucleic acid site by the target substance by the target substance detection method of the present invention.
- ATP was detected by the method for detecting a target substance of the present invention using an ATP aptamer and a nucleic acid fragment not containing a spacer sequence.
- FIG. 15 shows the ATP aptamer (sequence 15) and the nucleic acid fragment (sequence 3) complementary to the ATP aptamer used in this example.
- Sequence 15 is obtained by changing the spacer sequence portion of the ATP aptamer (sequence 2) used in the first example to a base sequence complementary to the portion used as the spacer of sequence 3. That is, when the ATP aptamer of sequence 15 and the nucleic acid fragment of sequence 3 are immobilized on the same member, the spacer length is zero and the number of bases forming a double-stranded nucleic acid site is 12. Further, among the double-stranded nucleic acid sites, the 5 bases on the substrate side are marginal sequences that do not participate in the binding to ATP.
- Array 15 and Array 3 were immobilized on a gold electrode in the same manner as in Example 1, and ATP was added to a final concentration of 1 mM while performing ACV measurement.
- FIG. 20 shows the time change of the ACV peak current in the above measurement.
- the current value was normalized based on the peak current immediately before the addition of ATP.
- the peak current began to increase immediately after the addition of ATP, and finally showed a value about 2.5 times that before the addition. Since the current value before addition of ATP was almost constant, it can be said that this increase in current is specific to ATP.
- the ATP aptamer and the nucleic acid fragment fixed on the electrode form a double-stranded nucleic acid site by a complementary base sequence.
- the base sequence near the substrate cannot form a double-stranded nucleic acid site due to steric hindrance with the substrate, but a complementary base sequence long enough to form a stable double-stranded region at a position away from the substrate.
- the double-stranded nucleic acid site is cleaved by binding of ATP and the ATP aptamer, and the current value increases.
- the optimum spacer length in the target substance detection method of the present invention varies depending on the number of complementary bases capable of forming a double-stranded nucleic acid site, and the spacer sequence may be omitted.
- the double-stranded nucleic acid site may contain a marginal sequence that does not participate in binding to the target substance.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Materials Engineering (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
検体試料中の標的物質が特異的に結合するアプタマーと、
前記アプタマーと相補的な塩基配列を有する第1の核酸断片と、
前記アプタマーの一部及び前記第1の核酸断片の一部が固定された固定部材と、
を備え、
前記アプタマーは、前記第1の核酸断片と二本鎖を形成する二本鎖形成部位を有している、複合体を準備する工程と、
前記標的物質を前記アプタマーに結合させることにより、前記第1の核酸断片を前記アプタマーの前記二本鎖形成部位から分離させる工程と、
前記第1の核酸断片が前記アプタマーから分離する、前記二本鎖の開裂を検出する工程と、
を有する標的物質の検出方法が提供される。
検体試料中の標的物質が特異的に結合するアプタマーと、
前記アプタマーと相補的な塩基配列を有する第1の核酸断片と、
前記アプタマーの一部及び前記第1の核酸断片の一部が固定された固定部材と、を備えており、
前記アプタマーは、前記第1の核酸断片と二本鎖を形成する二本鎖形成部位を有している、複合体からなる、
標的物質の検出に用いるセンサチップが提供される。
上記センサチップと、
前記アプタマーに標的物質を結合させる結合部と、
前記二本鎖の開裂を検出する検出部と、
を備える標的物質の検出装置が提供される。
第1の実施の形態について、図6を用いて説明する。
本実施の形態では、本発明に係る標的物質の検出方法および標的物質検出用のセンサの一例を示す。
また、固定部材4に固定されたとは、二本鎖形成を構成する水素結合を除いた、化学結合及び/又は化学吸着により結合されることを意味する。また、二本鎖の開裂を検出する手法としては、各種の公知の手段を用いることができ、具体的には後述する。
まず、複合体11を用意する。この複合体11は、アプタマー1と、第1の核酸断片2と、固定部材4を有している。アプタマー1の端部と第1の核酸断片2の端部は、固定部材4に化学結合および化学吸着により固定されている。本実施の形態では、アプタマー1の端部及び第1の核酸断片2の端部が、直接固定部材4に固定される。さらに、アプタマー1は、標的物質との結合を形成可能な塩基配列のうち少なくとも一部が第1の核酸断片2と二本鎖形成部位5を形成している(図6(a))。また、第1の核酸断片2の先端部には標識物質3が結合されている。第1の実施の形態において、二本鎖形成部位5(二本鎖核酸部位)とは、アプタマーとその相補的な配列を有する核酸とが核酸の二本鎖を形成している部位を意味する。
また、センサチップにおいて、アプタマー1と第1の核酸断片2により形成される二本鎖形成部位5が、のりしろ配列を含まなくてもよい。また。センサチップにおいて、二本鎖形成部位5が、アプタマー1の端部以外に形成されていてもよい。また、センサチップにおいて、後述するように、アプタマー1と第1の核酸断片2とが、化学結合および化学吸着により結合した連結部を備え、連結部は、少なくとも1カ所が化学結合および化学吸着により部材に固定されてもよい。このように、センサチップにおいて、複合体11は、各実施の形態のものを適宜採用することができる。
第2の実施の形態では、複合体11は、アプタマー1の一部と第1の核酸断片2の一部とが互いに連結した連結部8を備えており、連結部8が固定部材4に固定されている。例えば、アプタマー1と第1の核酸断片2とが化学結合および化学吸着により連結されている。また、アプタマー1の一部と第1の核酸断片2の一部とはリンカー分子に結合していてもよい。以下、第2の実施の形態について説明する。図7は、第2の実施の形態における複合体11を示す図である。
第3の実施の形態は、第1の実施の形態および第2の実施の形態の応用であり、同様な点については説明を省略する。図8は、第3の実施の形態における標的物質の検出手法の手順を示す図である。第3の実施の形態においては、アプタマー1と、第1の核酸断片2とが、固定部材4に固定され、アプタマー1および第1の核酸断片2が二本鎖形成部位5を形成する点は第1~第2の実施の形態と同じであるが、標的物質7による二本鎖核酸部位の開裂を、第2の核酸断片10を用いて検出する。すなわち、第3の実施の形態の標的物質の検出方法は、二本鎖の開裂を検出する工程が、二本鎖形成部位5から分離した第1の核酸断片2に、第1の核酸断片2と相補的な塩基配列を有する第2の核酸断片10を結合させる工程と、第1の核酸断片2と第2の核酸断片10の結合を検出することにより、二本鎖の開裂を検出する工程と、を有するものである。
第4の実施の形態は、アプタマー1および第1の核酸断片2が同一の親溶媒性の部材に化学結合および化学吸着により固定された場合について説明する。本実施形態は、第1~第3の実施の形態の応用であり、同様な点については説明を省略する。
すなわち、本実施の形態では、固定部材4は、アプタマー1及び第1の核酸断片2が固定された固定領域(検出部13)とは別の領域に、親溶媒性の領域(補足部14)を有する。補足部14は、溶媒との親和性が高いために、溶媒中に含まれる第2の核酸断片10を、その表面に浸透することにより補足することができる。補足部14に補足された第2の核酸断片10は、その表面を移動し、検出部13に固定された第1の核酸断片2に容易に結合することができる。
第5の実施の形態では、親溶媒性部材(部材21)に第2の核酸断片10が固定された場合について、図10および図11を用いて説明する。すなわち、本実施の形態において、第2の核酸断片10を結合させる工程は、二本鎖形成部位5から分離した第1の核酸断片2に、基板(部材21)に固定された第2の核酸断片10を結合させる工程を有している。この基板(部材21)は、第2の核酸断片10が固定された固定領域(検出部13)とは別の領域に、親溶媒性の領域(補足部14)を有する。なお、本実施形態は第1~第4の実施の形態の応用であり、同様な点については説明を省略する。
すなわち、本実施の形態において、アプタマー1及び第1の核酸断片2、または第2の核酸断片10のいずれかが親溶媒性の部材(固定部材4又は部材21)の検出部に固定されている。部材の検出部における第1の核酸断片2と第2の核酸断片10との結合を検出することにより、アプタマー1と第1の核酸断片2との二本鎖の開裂を検出することができる。
第6の実施形態では、標的物質検出工程の途中でアプタマーと第1の核酸断片との二本鎖の結合力が動的に変化する標的物質の検出方法について説明する。すなわち、本実施形態の標的物質の検出工程は、アプタマーと第1の核酸断片との二本鎖の結合力を弱める開裂エネルギー投入工程と、アプタマーと第1の核酸断片との二本鎖の結合力を強める二本鎖安定化工程を含んでいる。
本実施例では、アデノシン3リン酸(以下、ATP)と特異的に結合するATPアプタマーによって、本発明の標的物質の検出方法によりATPを検出した。
本発明の第3の実施形態に係る、第2の核酸断片の添加によるアプタマーと核酸断片の間の二本鎖核酸部位の開裂の検出を、シミュレーションにより検討した。
本実施例では、ATPアプタマーに対する相補的な塩基数が異なる核酸断片によって、本発明の標的物質の検出方法によりATPを検出した。すなわち、本実施例では、二本鎖核酸部位の長さが異なる場合の、ATP検出能力を比較した。
本実施例では、二本鎖核酸部位と基板間のスペーサ長さが異なるATPアプタマーおよび核酸断片によって、本発明の標的物質の検出方法によりATPを検出した。すなわち、本実施例では、スペーサの長さが異なる場合のATP検出能力を比較した。
本実施例では、第1の実施例と同様のアプタマーおよび核酸断片を使用して、ATP濃度と電流値の濃度依存性を調べた。
本実施例では、スペーサ配列を含まないATPアプタマーおよび核酸断片によって、本発明の標的物質の検出方法によりATPを検出した。
すなわち、電極上に固定されたATPアプタマーおよび核酸断片は、互いの相補な塩基配列によって二本鎖核酸部位を形成する。この際、基板に近い位置の塩基配列は基板との立体障害によって二本鎖核酸部位を形成できないが、基板から離れた位置に安定な二本鎖領域を形成できるだけの長さの相補な塩基配列が存在することにより、ATP添加前は低い電流値を示す。続いて、ATPが添加されると、ATPとATPアプタマーが結合することにより二本鎖核酸部位が開裂し、電流値が増加する。
また、本発明の標的物質の検出方法において、二本鎖核酸部位には標的物質との結合に関与しない、のりしろ配列を含んでいても良い。
Claims (14)
- 検体試料中の標的物質が特異的に結合するアプタマーと、
前記アプタマーと相補的な塩基配列を有する第1の核酸断片と、
前記アプタマーの一部及び前記第1の核酸断片の一部が固定された固定部材と、
を備え、
前記アプタマーは、前記第1の核酸断片と二本鎖を形成する二本鎖形成部位を有している、複合体を準備する工程と、
前記標的物質を前記アプタマーに結合させることにより、前記第1の核酸断片を前記アプタマーの前記二本鎖形成部位から分離させる工程と、
前記第1の核酸断片が前記アプタマーから分離する、前記二本鎖の開裂を検出する工程と、
を有する標的物質の検出方法。 - 前記アプタマーの前記二本鎖形成部位は、前記第1の核酸断片の塩基配列と相補的な塩基配列のみを有する請求項1に記載の標的物質の検出方法。
- 前記複合体は、前記アプタマーの一部と前記第1の核酸断片の一部とが互いに連結した連結部を備えており、
前記連結部が前記固定部材に固定されている請求項1または2に記載の標的物質の検出方法。 - 前記二本鎖の開裂を検出する工程は、
前記二本鎖形成部位から分離した前記第1の核酸断片に、前記第1の核酸断片と相補的な塩基配列を有する第2の核酸断片を結合させる工程と、
前記第1の核酸断片と前記第2の核酸断片の結合を検出することにより、前記二本鎖の開裂を検出する工程と、
を有する請求項1乃至3のいずれか一項に記載の標的物質の検出方法。 - 前記固定部材は、前記アプタマー及び前記第1の核酸断片が固定された固定領域とは別の領域に、親溶媒性の領域を有する請求項4に記載の標的物質の検出方法。
- 前記第2の核酸断片を結合させる工程は、前記二本鎖形成部位から分離した前記第1の核酸断片に、基板に固定された前記第2の核酸断片を結合させる工程を有しており、
前記基板は、前記第2の核酸断片が固定された固定領域とは別の領域に、親溶媒性の領域を有する請求項4に記載の標的物質の検出方法。 - 前記第2の核酸断片は、標識物質を有する請求項4乃至6のいずれか一項に記載の標的物質の検出方法。
- 前記複合体は、前記第1の核酸断片に結合した標識物質を備える請求項1乃至3のいずれか一項に記載の標的物質の検出方法。
- 前記第1の核酸断片を前記アプタマーの前記二本鎖形成部位から分離させる工程の前、または前記第1の核酸断片を前記アプタマーの前記二本鎖形成部位から分離させる工程において、前記アプタマーと前記第1の核酸断片との二本鎖の結合エネルギー以上の開裂エネルギーを投入する開裂エネルギー投入工程を含み、
前記二本鎖の開裂を検出する工程の前、または前記二本鎖の開裂を検出する工程において、前記アプタマーと前記第1の核酸断片との二本鎖の結合力を強める二本鎖安定化工程を含む請求項1乃至8のいずれか一項に記載の標的物質の検出方法。 - 前記第1の核酸断片を前記アプタマーの前記二本鎖形成部位から分離させる工程の前、または前記第1の核酸断片を前記アプタマーの前記二本鎖形成部位から分離させる工程において、前記アプタマーと前記第1の核酸断片との二本鎖の結合エネルギー未満の開裂エネルギーを投入する開裂エネルギー投入工程を含み、
前記二本鎖の開裂を検出する工程の前、または前記二本鎖の開裂を検出する工程において、前記アプタマーと前記第1の核酸断片との二本鎖の結合力を強める二本鎖安定化工程を含む請求項1乃至8のいずれか一項に記載の標的物質の検出方法。 - 前記開裂エネルギー投入工程は、測定液の温度上昇であり、
前記二本鎖安定化工程は、測定液の温度降下である請求項9または10に記載の標的物質の検出方法。 - 検体試料中の標的物質が特異的に結合するアプタマーと、
前記アプタマーと相補的な塩基配列を有する第1の核酸断片と、
前記アプタマーの一部及び前記第1の核酸断片の一部が固定された固定部材と、を備えており、
前記アプタマーは、前記第1の核酸断片と二本鎖を形成する二本鎖形成部位を有している、複合体からなる、
標的物質の検出に用いるセンサチップ。 - 請求項1から11のいずれか1項に記載の検出方法を用いて標的物質を検出することを特徴とする請求項12に記載のセンサチップ。
- 請求項12または13に記載のセンサチップと、
前記アプタマーに前記標的物質を結合させる結合部と、
前記二本鎖の開裂を検出する検出部と、
を備える標的物質の検出装置。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013525544A JP5949767B2 (ja) | 2011-07-25 | 2012-05-30 | 標的物質の検出方法 |
US14/234,844 US9340829B2 (en) | 2011-07-25 | 2012-05-30 | Method of detecting target material, sensor chip, and detecting device |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011162023 | 2011-07-25 | ||
JP2011-162023 | 2011-07-25 | ||
JP2012-046589 | 2012-03-02 | ||
JP2012046589 | 2012-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013014843A1 true WO2013014843A1 (ja) | 2013-01-31 |
Family
ID=47600721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/003538 WO2013014843A1 (ja) | 2011-07-25 | 2012-05-30 | 標的物質の検出方法、センサチップ、及び検出装置 |
Country Status (3)
Country | Link |
---|---|
US (1) | US9340829B2 (ja) |
JP (1) | JP5949767B2 (ja) |
WO (1) | WO2013014843A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013145939A1 (ja) * | 2012-03-28 | 2013-10-03 | 日本電気株式会社 | 標的物質の検出方法、検査キット、および検出装置 |
JP2015181384A (ja) * | 2014-03-24 | 2015-10-22 | 国立研究開発法人産業技術総合研究所 | 人工ヌクレアーゼの細胞への導入方法 |
WO2017073665A1 (ja) * | 2015-10-30 | 2017-05-04 | Necソリューションイノベータ株式会社 | 検出デバイスおよびこれを用いたターゲットの検出方法 |
WO2017138507A1 (ja) * | 2016-02-10 | 2017-08-17 | 日本電気株式会社 | Dna検査用チップ、dna検査方法、dna検査システム、及びdna検査チップ制御装置 |
WO2018151138A1 (ja) * | 2017-02-14 | 2018-08-23 | 国立研究開発法人理化学研究所 | 標的物質検出用核酸プローブ |
WO2018179514A1 (ja) * | 2017-03-27 | 2018-10-04 | Necソリューションイノベータ株式会社 | ステロイド骨格含有化合物検出デバイスおよびこれを用いたステロイド骨格含有化合物の検出方法 |
JP2018531387A (ja) * | 2016-07-14 | 2018-10-25 | 青島大学 | 核酸アプタマー/ナノ銀プローブとexo i酵素に基づく電気化学的バイオセンサ。 |
JP2019519773A (ja) * | 2016-06-03 | 2019-07-11 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨークThe Trustees Of Columbia University In The City Of New York | アプタマーベースの分析物アッセイ |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10852274B2 (en) | 2017-03-09 | 2020-12-01 | Auburn University | Differential circuit for background correction in electrochemical measurements |
US11505799B2 (en) | 2017-07-07 | 2022-11-22 | Innamed, Inc. | Aptamers for measuring lipoprotein levels |
US11560565B2 (en) | 2018-06-13 | 2023-01-24 | Auburn University | Electrochemical detection nanostructure, systems, and uses thereof |
US20230042710A1 (en) * | 2020-01-03 | 2023-02-09 | Innamed, Inc. | Electrochemical proximity assay |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005257667A (ja) * | 2004-02-09 | 2005-09-22 | Sony Corp | 物質間の相互作用を検出する検出表面と該検出表面を用いるセンサチップとセンサ装置及び検出方法 |
WO2008048310A2 (en) * | 2005-12-13 | 2008-04-24 | University Of Medicine And Dentistry Of New Jersey | Bimolecular constructs |
JP2008278837A (ja) * | 2007-05-14 | 2008-11-20 | Sony Corp | 検出用核酸鎖及び物質間の結合又は相互作用検出方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2373314C (en) | 1999-05-14 | 2010-09-14 | Brandeis University | Nucleic acid-based detection |
-
2012
- 2012-05-30 WO PCT/JP2012/003538 patent/WO2013014843A1/ja active Application Filing
- 2012-05-30 US US14/234,844 patent/US9340829B2/en active Active
- 2012-05-30 JP JP2013525544A patent/JP5949767B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005257667A (ja) * | 2004-02-09 | 2005-09-22 | Sony Corp | 物質間の相互作用を検出する検出表面と該検出表面を用いるセンサチップとセンサ装置及び検出方法 |
WO2008048310A2 (en) * | 2005-12-13 | 2008-04-24 | University Of Medicine And Dentistry Of New Jersey | Bimolecular constructs |
JP2008278837A (ja) * | 2007-05-14 | 2008-11-20 | Sony Corp | 検出用核酸鎖及び物質間の結合又は相互作用検出方法 |
Non-Patent Citations (6)
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9657333B2 (en) | 2012-03-28 | 2017-05-23 | Nec Coporation | Method for detecting target substance, assay kit, and detection apparatus |
JPWO2013145939A1 (ja) * | 2012-03-28 | 2015-12-10 | 日本電気株式会社 | 標的物質の検出方法、検査キット、および検出装置 |
WO2013145939A1 (ja) * | 2012-03-28 | 2013-10-03 | 日本電気株式会社 | 標的物質の検出方法、検査キット、および検出装置 |
JP2015181384A (ja) * | 2014-03-24 | 2015-10-22 | 国立研究開発法人産業技術総合研究所 | 人工ヌクレアーゼの細胞への導入方法 |
JPWO2017073665A1 (ja) * | 2015-10-30 | 2018-08-16 | Necソリューションイノベータ株式会社 | 検出デバイスおよびこれを用いたターゲットの検出方法 |
WO2017073665A1 (ja) * | 2015-10-30 | 2017-05-04 | Necソリューションイノベータ株式会社 | 検出デバイスおよびこれを用いたターゲットの検出方法 |
WO2017138507A1 (ja) * | 2016-02-10 | 2017-08-17 | 日本電気株式会社 | Dna検査用チップ、dna検査方法、dna検査システム、及びdna検査チップ制御装置 |
GB2563357A (en) * | 2016-02-10 | 2018-12-12 | Nec Corp | DNA testing chip, DNA testing method, DNA testing system, and DNA testing chip control device |
JP2019519773A (ja) * | 2016-06-03 | 2019-07-11 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨークThe Trustees Of Columbia University In The City Of New York | アプタマーベースの分析物アッセイ |
JP2018531387A (ja) * | 2016-07-14 | 2018-10-25 | 青島大学 | 核酸アプタマー/ナノ銀プローブとexo i酵素に基づく電気化学的バイオセンサ。 |
WO2018151138A1 (ja) * | 2017-02-14 | 2018-08-23 | 国立研究開発法人理化学研究所 | 標的物質検出用核酸プローブ |
WO2018179514A1 (ja) * | 2017-03-27 | 2018-10-04 | Necソリューションイノベータ株式会社 | ステロイド骨格含有化合物検出デバイスおよびこれを用いたステロイド骨格含有化合物の検出方法 |
JPWO2018179514A1 (ja) * | 2017-03-27 | 2019-11-21 | Necソリューションイノベータ株式会社 | ステロイド骨格含有化合物検出デバイスおよびこれを用いたステロイド骨格含有化合物の検出方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2013014843A1 (ja) | 2015-02-23 |
US9340829B2 (en) | 2016-05-17 |
JP5949767B2 (ja) | 2016-07-13 |
US20150050645A1 (en) | 2015-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5949767B2 (ja) | 標的物質の検出方法 | |
Tang et al. | Nanopore-based strategy for selective detection of single carcinoembryonic antigen (CEA) molecules | |
Li et al. | Development of a novel label-free impedimetric electrochemical sensor based on hydrogel/chitosan for the detection of ochratoxin A | |
Ren et al. | Target-driven triple-binder assembly of MNAzyme for amplified electrochemical immunosensing of protein biomarker | |
JP6123794B2 (ja) | 標的物質の検出方法、検査キット、および検出装置 | |
Wang et al. | A novel “signal-on/off” sensing platform for selective detection of thrombin based on target-induced ratiometric electrochemical biosensing and bio-bar-coded nanoprobe amplification strategy | |
Ren et al. | Proximity hybridization regulated DNA biogate for sensitive electrochemical immunoassay | |
Yin | Functional nucleic acids for electrochemical and electrochemiluminescent sensing applications | |
US20160061766A1 (en) | Electrochemical proximity assay | |
US20100248231A1 (en) | High specificity and high sensitivity detection based on steric hindrance & enzyme-related signal amplification | |
Zhang et al. | Label-free cascade amplification strategy for sensitive visual detection of thrombin based on target-triggered hybridization chain reaction-mediated in situ generation of DNAzymes and Pt nanochains | |
Alizadeh et al. | Hemin/G-Quadruplex horseradish peroxidase-mimicking DNAzyme: principle and biosensing application | |
Tombelli et al. | Aptamers as molecular tools for bioanalytical methods | |
US20130157279A1 (en) | Method for detecting target substance and aptamer set, sensor, and apparatus used in the method | |
Hu et al. | The sandwich-type aptasensor based on gold nanoparticles/DNA/magnetic beads for detection of cancer biomarker protein AGR2 | |
Fang et al. | Unambiguous discrimination of multiple protein biomarkers by nanopore sensing with double-stranded DNA-based probes | |
CN112725343A (zh) | 联合金纳米探针和CRISPR-Cas的蛋白标志物检测试剂盒及检测方法 | |
Chen et al. | A multifunctional label-free electrochemical impedance biosensor for Hg2+, adenosine triphosphate and thrombin | |
Zhao et al. | An electrochemical aptasensor for thrombin detection based on the recycling of exonuclease III and double-stranded DNA-templated copper nanoparticles assisted signal amplification | |
Zhai et al. | A homogeneous DNA nanosphere for fluorescence detection of microRNAs with high-ordered aggregation enhanced emission and enzyme-free cascade amplification | |
Yao et al. | An aptamer-based chemiluminescence method for ultrasensitive detection of platelet-derived growth factor by cascade amplification combining rolling circle amplification with hydroxylamine-enlarged gold nanoparticles | |
Liu et al. | An antifouling interface integrated with HRP-based amplification to achieve a highly sensitive electrochemical aptasensor for lysozyme detection | |
Xue et al. | Aptamer-based exonuclease protection and enzymatic recycling cleavage amplification homogeneous assay for the highly sensitive detection of thrombin | |
Peng et al. | Impedimetric aptasensor for nuclear factor kappa B with peroxidase-like mimic coupled DNA nanoladders as enhancer | |
Song et al. | Target-induced site-specific cleavage of phosphorothioate-modified hairpin DNA for amplified and label-free sensitive electrochemical myeloperoxidase assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12817368 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013525544 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14234844 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12817368 Country of ref document: EP Kind code of ref document: A1 |